+44 (0)20 8817 5296info@tritrials.com

The maturing of RBM implementation

  As we at TRI continue to engage with industry on RBM implementation, I am pleased with the observations that we are currently making across a range of CRO and Pharma companies. Rolling back the clock 18-24 months and most of the discussions we were having with customers and prospects were about risk detection, data visualisation and stats models….

Read More

TRI selected to present on RBM at 51st Annual DIA

The title of Tammy’s presentation will be  “Therapeutic Area Key Risk Indicators:  Digestive Disease”. The content in the presentation will be based on the experience gained from one of our RBM pilots being run using TRI’s RBM platform, OPRA. The presentation aims to take the audience through the journey of the project team, outlining the objectives of the project,…

Read More